Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
37
pubmed:dateCreated
2002-9-10
pubmed:abstractText
Relative to the gray matter, there is a paucity of information regarding white matter biochemical alterations and their contribution to Alzheimer's disease (AD). Biochemical analyses of AD white matter combining size-exclusion, normal phase, and gas chromatography, immunoassays, and Western blotting revealed increased quantities of Abeta40 and Abeta42 in AD white matter accompanied by significant decreases in the amounts of myelin basic protein, myelin proteolipid protein, and 2',3'-cyclic nucleotide 3'-phosphodiesterase. In addition, the AD white matter cholesterol levels were significantly decreased while total fatty acid content was increased. In some instances, these white matter biochemical alterations were correlated with patient apolipoprotein E genotype, Braak stage, and gender. Our observations suggest that extensive white matter axonal demyelination underlies Alzheimer's pathology, resulting in loss of capacitance and serious disturbances in nerve conduction, severely damaging brain function. These white matter alterations undoubtedly contribute to AD pathogenesis and may represent the combined effects of neuronal degeneration, microgliosis, oligodendrocyte injury, microcirculatory disease, and interstitial fluid stasis. To accurately assess the success of future therapeutic interventions, it is necessary to have a complete appreciation of the full scope and extent of AD pathology.
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Sep
pubmed:issn
0006-2960
pubmed:author
pubmed:issnType
Print
pubmed:day
17
pubmed:volume
41
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
11080-90
pubmed:dateRevised
2010-11-18
pubmed:meshHeading
pubmed-meshheading:12220172-Aged, pubmed-meshheading:12220172-Aged, 80 and over, pubmed-meshheading:12220172-Aging, pubmed-meshheading:12220172-Alzheimer Disease, pubmed-meshheading:12220172-Amyloid beta-Peptides, pubmed-meshheading:12220172-Cerebral Cortex, pubmed-meshheading:12220172-Cholesterol, pubmed-meshheading:12220172-Demyelinating Diseases, pubmed-meshheading:12220172-Fatty Acids, pubmed-meshheading:12220172-Female, pubmed-meshheading:12220172-Humans, pubmed-meshheading:12220172-Male, pubmed-meshheading:12220172-Middle Aged, pubmed-meshheading:12220172-Myelin Basic Proteins, pubmed-meshheading:12220172-Myelin Proteins, pubmed-meshheading:12220172-Myelin Proteolipid Protein, pubmed-meshheading:12220172-Myelin Sheath, pubmed-meshheading:12220172-Oligodendroglia, pubmed-meshheading:12220172-Peptide Fragments, pubmed-meshheading:12220172-Phosphoric Diester Hydrolases
pubmed:year
2002
pubmed:articleTitle
Increased A beta peptides and reduced cholesterol and myelin proteins characterize white matter degeneration in Alzheimer's disease.
pubmed:affiliation
The Longtine Center for Molecular Biology and Genetics and Harold Civin Laboratory of Neuropathology, Sun Health Research Institute, Sun City, Arizona 85351, USA. alex.roher@sunbreath.org
pubmed:publicationType
Journal Article, Research Support, U.S. Gov't, P.H.S., Research Support, Non-U.S. Gov't